Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Dapansutrile - Olatec Therapeutics

Next Previous
X
Search
Drug Profile

Dapansutrile - Olatec Therapeutics

Alternative Names: OLT 1177; OLT1177

Latest Information Update: 28 Nov 2024

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Olatec Industries
  • Developer Olatec Therapeutics; University of Innsbruck
  • Class Analgesics; Anti-inflammatories; Anti-ischaemics; Antiasthmatics; Antidementias; Antigouts; Antineoplastics; Antiparkinsonians; Antirheumatics; Antivirals; Cardiovascular therapies; Heart failure therapies; Nitriles; Skin disorder therapies; Small molecules; Sulfones
  • Mechanism of Action Inflammasome inhibitors; Interleukin 1 beta inhibitors; Interleukin 18 inhibitors; Interleukin inhibitors; NLRP3 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II/III Gout
  • Phase II COVID 2019 infections; Musculoskeletal pain; Schnitzler syndrome; Type 2 diabetes mellitus
  • Phase I/II Malignant melanoma
  • Preclinical Pancreatic cancer; Parkinson's disease
  • No development reported Alzheimer's disease; Arthritis; Asthma; Breast cancer; Contact dermatitis; Heart failure; Multiple sclerosis; Myocardial infarction; Myocardial reperfusion injury; Spinal cord injuries

Most Recent Events

  • 28 Nov 2024 No recent reports of development identified for preclinical development in Alzheimer's-disease in USA (PO)
  • 28 Nov 2024 No recent reports of development identified for preclinical development in Arthritis in USA
  • 28 Nov 2024 No recent reports of development identified for preclinical development in Asthma in USA

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top